Get the Stockscreener App
2.40
0.00%
0.00
After Hours:
2.42
0.02
+0.83%
Gri Bio Inc stock is traded at $2.40, with a volume of 19,242.
It is up +0.00% in the last 24 hours and up +9.59% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$2.40
Open:
$2.42
24h Volume:
19,242
Relative Volume:
0.05
Market Cap:
$3.47M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.0448
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
-6.98%
1M Performance:
+9.59%
6M Performance:
-94.84%
1Y Performance:
-98.76%
1-Day Range:
$2.32
$2.45
1-Week Range:
$2.26
$2.66
52-Week Range:
$2.10
$311.36
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
2.40 | 3.47M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
Short Covering: What makes GRI Bio Inc stock attractive todayWeekly Earnings Recap & High Win Rate Trade Tips - baoquankhu1.vn
GRI PE Ratio & Valuation, Is GRI Overvalued - Intellectia AI
Aug Drivers: Is GRI Bio Inc a top pick in the sector2025 Price Action Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
GRI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Loss Report: Is GRI Bio Inc stock a smart retirement pickWeekly Gains Report & AI Based Buy and Sell Signals - baoquankhu1.vn
Geopolitics Watch: Can GRI Bio Inc reach all time highs this yearPortfolio Growth Summary & AI Forecast Swing Trade Picks - baoquankhu1.vn
Growth Review: Is GRI Bio Inc stock a smart retirement pick2025 Analyst Calls & Weekly Top Performers Watchlists - baoquankhu1.vn
Is GRI Bio Inc. a momentum stockJuly 2025 Movers & Technical Buy Zone Confirmations - mfd.ru
Market Leaders: What dividend growth rate does CHGG offerJuly 2025 Action & Verified Short-Term Plans - baoquankhu1.vn
Investor Mood: Is GRI Bio Inc stock a smart retirement pickQuarterly Risk Review & Real-Time Volume Surge Alerts - baoquankhu1.vn
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment - The Globe and Mail
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor 'What This Means” Segment - The Manila Times
GRI Bio, Inc. Discusses Positive Phase 2a Data in Idiopathic Pulmonary Fibrosis During Virtual Investor Segment - Quiver Quantitative
New IPF trial data: GRI Bio CEO explains lung repair signals - Stock Titan
Can GRI Bio Inc. stock maintain growth trajectoryProduct Launch & AI Powered Market Entry Strategies - mfd.ru
[SCHEDULE 13G/A] GRI Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data - MSN
Is GRI Bio Inc. showing insider buyingJuly 2025 PreEarnings & Daily Technical Stock Forecast Reports - mfd.ru
GRI Bio: Positive phase 2A IPF results and IND plans for lupus program signal strong pipeline momentum - TradingView
GRI Bio: Positive phase 2A IPF data and pipeline progress position GRI Bio for key upcoming milestones - TradingView
Can GRI Bio Inc. reach all time highs this yearStock Surge & Free Growth Oriented Trading Recommendations - mfd.ru
Levels Update: Is now the right time to enter SHF Holdings IncPortfolio Value Report & Verified Momentum Stock Watchlist - baoquankhu1.vn
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Yahoo Finance
GRI Bio reports $8.2 million cash position, extends runway into Q1 2027 - Investing.com Canada
GRI Bio sees cash runway into 1Q27 - TipRanks
GRI Bio raises $14.5 mln to fund operations into Q1 2027 - TradingView
GRI Bio: Strong cash position and positive clinical data support continued pipeline advancement - TradingView
GRI Bio, Inc. Reports Strong Cash Position and Positive Phase 2a Results for GRI-0621 in Pulmonary Fibrosis - Quiver Quantitative
GRI Bio Reiterates Full Year 2025 Financial Results, - GlobeNewswire
GRI Bio (GRI) Price Target Increased by 2,700.00% to 656.88 - Nasdaq
Dip Buying: Is CALX forming bullish engulfing patternsForecast Cut & Free Reliable Trade Execution Plans - baoquankhu1.vn
Aug Summary: What makes GRI Bio Inc stock attractive todayJuly 2025 Rallies & Low Drawdown Trading Techniques - baoquankhu1.vn
Trading Recap: Can OACCU deliver consistent dividendsJuly 2025 Final Week & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Gri Bio Warns of Ongoing Internal Control Weaknesses That Could Threaten Financial Reporting Reliability and Investor Confidence - TipRanks
Rate Cut: Is GRI Bio Inc forming a double bottomQuarterly Portfolio Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Buyback Watch: Is JVSPAC Acquisition Corp Equity Right a momentum stockEarnings Overview Summary & Low Risk Entry Point Tips - baoquankhu1.vn
GRI Bio: 2025 net loss rose to $12M as R&D spending increased; more capital needed for future trials - TradingView
GRI Bio, Inc. SEC 10-K Report - TradingView
GRI Bio Expands At-The-Market Equity Offering Capacity - TipRanks
GRI Bio May Offer Up To $250 Million In SecuritiesSEC Filing - TradingView
Movement Recap: Can GRI Bio Inc be recession proof2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened? - Asianet Newsable
GRI Bio reports positive gene expression data for IPF drug candidate - Investing.com Nigeria
What’s the RSI of GRI Bio Inc. stockQuarterly Portfolio Review & AI Forecasted Stock Moves - mfd.ru
GRI Bio delivers additional data from Phase 2a study of GRI-0621 - TipRanks
GRI Bio Reports New Phase 2a Gene Expression Data Supporting Anti-Fibrotic Activity Of GRI-0621 - Nasdaq
GRI Bio reports promising Phase 2a data in IPF - TipRanks
GRI Bio stock soars after gene data shows IPF drug targets disease drivers - Investing.com Nigeria
GRI Bio stock soars after gene data shows IPF drug targets disease drivers By Investing.com - Investing.com South Africa
GRI Bio, Inc. Announces Positive Phase 2a Clinical Trial Data for GRI-0621 - TradingView
GRI Bio, Inc. Reports Positive Phase 2a Results for GRI-0621 as Disease-Modifying Therapy in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):